b Huntington Ingalls nabs $187.1M for overhaul of USS John C. Stennis By www.upi.com Published On :: Wed, 06 May 2020 20:04:45 -0400 Huntington Ingalls was awarded a $187.1 million contract modification Wednesday for the refueling complex overhaul of USS John C. Stennis, according to the Pentagon. Full Article
b Blue Angels to fly over Jacksonville, Miami on Friday By www.upi.com Published On :: Thu, 07 May 2020 15:45:25 -0400 The U.S. Navy Flight Demonstration Squadron, the Blue Angels, will fly over Jacksonville and Miami, Fla., Friday as part of a nationwide tour to show appreciation for healthcare workers and frontline responders. Full Article
b Navy breaks ground on laser weapons test lab in California By www.upi.com Published On :: Thu, 07 May 2020 18:29:45 -0400 Navy leaders and private contractors broke ground this week on what will become the fleet's only dedicated facility to test, fire and evaluate complete laser weapon systems in a maritime environment. Full Article
b Boeing awarded $128.5M modification to GMD missile upgrade contract By www.upi.com Published On :: Thu, 07 May 2020 19:36:45 -0400 Boeing was awarded a $128.5 million modification to its Ground-based Midcourse Defense development and sustainment contract Thursday, according to the Pentagon. Full Article
b Raytheon nabs $19M for RAM missiles, GMLS launchers By www.upi.com Published On :: Thu, 07 May 2020 20:03:58 -0400 Raytheon Missile Systems was awarded a $19 million contract modification to exercise options for Navy Rolling Airframe Missile and Guided Missile Launching Systems, according to the Department of Defense. Full Article
b Starting Aug. 1, DoD sites won't sell tobacco to people under 21 By www.upi.com Published On :: Fri, 08 May 2020 13:49:52 -0400 The Department of Defense announced this week that effective Aug. 1, retailers on U.S. military installations and bases will no longer sell tobacco products to anyone under the age of 21, including service members. Full Article
b Gestational Diabetes Mellitus and Diet: A Systematic Review and Meta-analysis of Randomized Controlled Trials Examining the Impact of Modified Dietary Interventions on Maternal Glucose Control and Neonatal Birth Weight By care.diabetesjournals.org Published On :: 2018-07-01 Jennifer M. YamamotoJul 1, 2018; 41:1346-1361Reconsidering Pregnancy With Diabetes Full Article
b Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the American Heart Association and American Diabetes Association By care.diabetesjournals.org Published On :: 2014-10-01 Sarah D. de FerrantiOct 1, 2014; 37:2843-2863Scientific Statement Full Article
b Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors By care.diabetesjournals.org Published On :: 2018-08-01 David C. KlonoffAug 1, 2018; 41:1681-1688Emerging Technologies: Data Systems and Devices Full Article
b Diabetes and Aging: Unique Considerations and Goals of Care By care.diabetesjournals.org Published On :: 2017-04-01 Rita R. KalyaniApr 1, 2017; 40:440-443Emerging Science and Concepts for Management of Diabetes and Aging Full Article
b Table 1--Systeme International (SI) units for plasma, serum, or blood concentrations By care.diabetesjournals.org Published On :: 1994-04-01 Apr 1, 1994; 17:360-361Syst[egrave]me International (SI) Units Full Article
b Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease By care.diabetesjournals.org Published On :: 2020-05-01 Gregory G. SchwartzMay 1, 2020; 43:1077-1084Emerging Therapies: Drugs and Regimens Full Article
b Table 1--Systeme International (SI) units for plasma, serum, or blood concentrations By care.diabetesjournals.org Published On :: 1995-11-01 Nov 1, 1995; 18:1524-1525Syst[egrave]me International (SI) Units Full Article
b Professional Practice Committee: Standards of Medical Care in Diabetes--2019 By care.diabetesjournals.org Published On :: 2019-01-01 Jan 1, 2019; 42:S3-S3Professional Practice Committee Full Article
b Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030 By care.diabetesjournals.org Published On :: 2018-05-01 Christian BommerMay 1, 2018; 41:963-970The Costs Of Diabetes Full Article
b Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations By care.diabetesjournals.org Published On :: 2016-06-01 Francesco RubinoJun 1, 2016; 39:861-877Metabolic Surgery and the Changing Landscape for Diabetes Care Full Article
b HbA1c Levels Are Significantly Lower in Early and Late Pregnancy By care.diabetesjournals.org Published On :: 2004-05-01 Lene R. NielsenMay 1, 2004; 27:1200-1201Brief Reports Full Article
b Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association By care.diabetesjournals.org Published On :: 2015-10-01 Richard A. InselOct 1, 2015; 38:1964-1974Scientific Statement Full Article
b Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study By care.diabetesjournals.org Published On :: 2016-10-01 Khalid A. JadoonOct 1, 2016; 39:1777-1786Emerging Technologies and Therapeutics Full Article
b PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes By care.diabetesjournals.org Published On :: 2019-09-01 Vanita R. ArodaSep 1, 2019; 42:1724-1732Emerging Therapies: Drugs and Regimens Full Article
b Disclosures: Standards of Medical Care in Diabetes--2020 By care.diabetesjournals.org Published On :: 2020-01-01 Jan 1, 2020; 43:S205-S206Disclosures Full Article
b Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era By care.diabetesjournals.org Published On :: 2015-06-01 Kirstine J. BellJun 1, 2015; 38:1008-1015Type 1 Diabetes at a Crossroads Full Article
b Current Challenges and Opportunities in the Prevention and Management of Diabetic Foot Ulcers By care.diabetesjournals.org Published On :: 2018-04-01 William J. JeffcoateApr 1, 2018; 41:645-652Perspectives in Care Full Article
b Dietary Sugar and Body Weight: Have We Reached a Crisis in the Epidemic of Obesity and Diabetes?: Health Be Damned! Pour on the Sugar By care.diabetesjournals.org Published On :: 2014-04-01 George A. BrayApr 1, 2014; 37:950-956Current Concepts of Type 2 Diabetes Prevention Full Article
b The Pros and Cons of Diagnosing Diabetes With A1C By care.diabetesjournals.org Published On :: 2011-05-01 Enzo BonoraMay 1, 2011; 34:S184-S190Diabetes Full Article
b The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview By care.diabetesjournals.org Published On :: 2014-01-01 David M. NathanJan 1, 2014; 37:9-16DCCT/EDIC 30th Anniversary Summary Findings Full Article
b Management of Inpatient Hyperglycemia and Diabetes in Older Adults By care.diabetesjournals.org Published On :: 2017-04-01 Guillermo E. UmpierrezApr 1, 2017; 40:509-517Emerging Science and Concepts for Management of Diabetes and Aging Full Article
b DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors By care.diabetesjournals.org Published On :: 2011-05-01 Dror DickerMay 1, 2011; 34:S276-S278Diabetes Treatments Full Article
b SGLT2 Inhibitors and the Diabetic Kidney By care.diabetesjournals.org Published On :: 2016-08-01 Paola FiorettoAug 1, 2016; 39:S165-S171III. SGLT2 Therapy Full Article
b Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability By care.diabetesjournals.org Published On :: 2011-05-01 Alan J. GarberMay 1, 2011; 34:S279-S284Diabetes Treatments Full Article
b Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors Expert Forum By care.diabetesjournals.org Published On :: 2018-01-01 William T. CefaluJan 1, 2018; 41:14-31Diabetes Care Expert Forum Full Article
b What Should Be the Target Blood Pressure in Elderly Patients With Diabetes? By care.diabetesjournals.org Published On :: 2016-08-01 Anna SoliniAug 1, 2016; 39:S234-S243VI. Cardiovascular Risk and Diabetes Full Article
b Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial By care.diabetesjournals.org Published On :: 2020-05-01 W. Timothy GarveyMay 1, 2020; 43:1085-1093Emerging Therapies: Drugs and Regimens Full Article
b Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial By care.diabetesjournals.org Published On :: 2019-12-01 Helena W. RodbardDec 1, 2019; 42:2272-2281Emerging Therapies: Drugs and Regimens Full Article
b The Cost of Diabetes Care--An Elephant in the Room By care.diabetesjournals.org Published On :: 2018-05-01 Matthew C. RiddleMay 1, 2018; 41:929-932The Costs Of Diabetes Full Article
b Diabetes Technology Update: Use of Insulin Pumps and Continuous Glucose Monitoring in the Hospital By care.diabetesjournals.org Published On :: 2018-08-01 Guillermo E. UmpierrezAug 1, 2018; 41:1579-1589Diabetes Care Symposium Full Article
b Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes By care.diabetesjournals.org Published On :: 2013-08-01 Itamar RazAug 1, 2013; 36:S139-S144Diabetes Pathophysiology Full Article
b Globalization of Diabetes: The role of diet, lifestyle, and genes By care.diabetesjournals.org Published On :: 2011-06-01 Frank B. HuJun 1, 2011; 34:1249-1257Kelly West Award Lecture Full Article
b 2017 National Standards for Diabetes Self-Management Education and Support By care.diabetesjournals.org Published On :: 2017-10-01 Joni BeckOct 1, 2017; 40:1409-1419National Standards Full Article
b Effects of Coffee Consumption on Fasting Blood Glucose and Insulin Concentrations: Randomized controlled trials in healthy volunteers By care.diabetesjournals.org Published On :: 2004-12-01 Rob M. van DamDec 1, 2004; 27:2990-2992Brief Reports Full Article
b Treatment of Type 2 Diabetes: From "Guidelines" to "Position Statements" and Back: Recommendations of the Israel National Diabetes Council By care.diabetesjournals.org Published On :: 2016-08-01 Ofri MosenzonAug 1, 2016; 39:S146-S153II. Diabetes Treatment Options Full Article
b Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association By care.diabetesjournals.org Published On :: 2016-12-01 Deborah Young-HymanDec 1, 2016; 39:2126-2140Psychosocial Research and Care in Diabetes Full Article
b Table 1-Systeme International (SI) units for plasma, serum, or blood concentrations By care.diabetesjournals.org Published On :: 1995-08-01 Aug 1, 1995; 18:1223-1224Syst[egrave]me International (SI) Units Full Article
b Economic Costs of Diabetes in the U.S. in 2017 By care.diabetesjournals.org Published On :: 2018-05-01 American Diabetes AssociationMay 1, 2018; 41:917-928The Costs Of Diabetes Full Article
b 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) By care.diabetesjournals.org Published On :: 2020-02-01 John B. BuseFeb 1, 2020; 43:487-493Consensus Report Update Full Article
b Professional Practice Committee: Standards of Medical Care in Diabetes--2020 By care.diabetesjournals.org Published On :: 2020-01-01 Jan 1, 2020; 43:S3-S3Professional Practice Committee Full Article
b Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report By care.diabetesjournals.org Published On :: 2019-05-01 Alison B. EvertMay 1, 2019; 42:731-754Continuing Evolution of Nutritional Therapy for Diabetes Full Article
b Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC By care.diabetesjournals.org Published On :: 2020-01-20T12:00:30-08:00 OBJECTIVE The MHC region harbors the strongest loci for latent autoimmune diabetes in adults (LADA); however, the strength of association is likely attenuated compared with that for childhood-onset type 1 diabetes. In this study, we recapitulate independent effects in the MHC class I region in a population with type 1 diabetes and then determine whether such conditioning in LADA yields potential genetic discriminators between the two subtypes within this region. RESEARCH DESIGN AND METHODS Chromosome 6 was imputed using SNP2HLA, with conditional analysis performed in type 1 diabetes case subjects (n = 1,985) and control subjects (n = 2,219). The same approach was applied to a LADA cohort (n = 1,428) using population-based control subjects (n = 2,850) and in a separate replication cohort (656 type 1 diabetes case, 823 LADA case, and 3,218 control subjects). RESULTS The strongest associations in the MHC class II region (rs3957146, β [SE] = 1.44 [0.05]), as well as the independent effect of MHC class I genes, on type 1 diabetes risk, particularly HLA-B*39 (β [SE] = 1.36 [0.17]), were confirmed. The conditional analysis in LADA versus control subjects showed significant association in the MHC class II region (rs3957146, β [SE] = 1.14 [0.06]); however, we did not observe significant independent effects of MHC class I alleles in LADA. CONCLUSIONS In LADA, the independent effects of MHC class I observed in type 1 diabetes were not observed after conditioning on the leading MHC class II associations, suggesting that the MHC class I association may be a genetic discriminator between LADA and childhood-onset type 1 diabetes. Full Article
b Steroid Metabolomic Signature of Insulin Resistance in Childhood Obesity By care.diabetesjournals.org Published On :: 2020-01-20T12:00:30-08:00 OBJECTIVE On the basis of urinary steroidal gas chromatography-mass spectrometry (GC-MS), we previously defined a novel concept of a disease-specific "steroid metabolomic signature" and reclassified childhood obesity into five groups with distinctive signatures. The objective of the current study was to delineate the steroidal signature of insulin resistance (IR) in obese children. RESEARCH DESIGN AND METHODS Urinary samples of 87 children (44 girls) aged 8.5–17.9 years with obesity (BMI >97th percentile) were quantified for 31 steroid metabolites by GC-MS. Defined as HOMA-IR >95th percentile and fasting glucose-to-insulin ratio >0.3, IR was diagnosed in 20 (of 87 [23%]) of the examined patients. The steroidal fingerprints of subjects with IR were compared with those of obese children without IR (non-IR). The steroidal signature of IR was created from the product of IR – non-IR for each of the 31 steroids. RESULTS IR and non-IR groups of children had comparable mean age (13.7 ± 1.9 and 14.6 ± 2.4 years, respectively) and z score BMI (2.7 ± 0.5 and 2.7 ± 0.5, respectively). The steroidal signature of IR was characterized by high adrenal androgens, glucocorticoids, and mineralocorticoid metabolites; higher 5α-reductase (An/Et) (P = 0.007) and 21-hydroxylase [(THE + THF + αTHF)/PT] activity (P = 0.006); and lower 11βHSD1 [(THF + αTHF)/THE] activity (P = 0.012). CONCLUSIONS The steroidal metabolomic signature of IR in obese children is characterized by enhanced secretion of steroids from all three adrenal pathways. As only the fasciculata and reticularis are stimulated by ACTH, these findings suggest that IR directly affects the adrenals. We suggest a vicious cycle model, whereby glucocorticoids induce IR, which could further stimulate steroidogenesis, even directly. We do not know whether obese children with IR and the new signature may benefit from amelioration of their hyperadrenalism. Full Article
b Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes By care.diabetesjournals.org Published On :: 2020-01-20T12:00:30-08:00 OBJECTIVE To determine if the International Hypoglycaemia Study Group (IHSG) level 2 low glucose definition can identify clinically relevant hypoglycemia in clinical trials and offer value as an end point for future trials. RESEARCH DESIGN AND METHODS A post hoc analysis was performed of the SWITCH (SWITCH 1: n = 501, type 1 diabetes; SWITCH 2: n = 721, type 2 diabetes) and DEVOTE (n = 7,637, type 2 diabetes) trials utilizing the IHSG low glucose definitions. Patients in all trials were randomized to either insulin degludec or insulin glargine 100 units/mL. In the main analysis, the following definitions were compared: 1) American Diabetes Association (ADA) 2005 (plasma glucose [PG] confirmed ≤3.9 mmol/L with symptoms); and 2) IHSG level 2 (PG confirmed <3.0 mmol/L, independent of symptoms). RESULTS In SWITCH 2, the estimated rate ratios of hypoglycemic events indicated increasing differences between treatments with decreasing PG levels until 3.0 mmol/L, following which no additional treatment differences were observed. Similar results were observed for the SWITCH 1 trial. In SWITCH 2, the IHSG level 2 definition produced a rate ratio that was lower than the ADA 2005 definition. CONCLUSIONS The IHSG level 2 definition was validated in a series of clinical trials, demonstrating its ability to discriminate between basal insulins. This definition is therefore recommended to be uniformly adopted by regulatory bodies and used in future clinical trials. Full Article
